Joseph Gall
Hematology & Oncology · Greensburg, PANPI 1508938192
Payments from drug & device makers
Across 332 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$782
- Johnson & Johnson$743
- Pfizer$636
- Amgen$581
- Astellas Pharma US Inc$547
- Pharmacyclics LLC, An Abbvie Company$450
- plus $3K from 23 others
What the payments were for
- Food & beverage$6,25996%
- Education$2294%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 39 | $782 |
| Johnson & Johnson(2 entities) | 35 | $743 |
| Pfizer | 32 | $636 |
| Amgen | 34 | $581 |
| Astellas Pharma US Inc | 30 | $547 |
| Pharmacyclics LLC, An Abbvie Company | 16 | $450 |
| Gilead(2 entities) | 24 | $426 |
| Rigel Pharmaceuticals, Inc. | 22 | $360 |
| Novartis | 17 | $334 |
| AstraZeneca | 14 | $272 |
| Dendreon Pharmaceuticals LLC | 11 | $240 |
| Incyte Corporation | 11 | $197 |
| E.r. Squibb & Sons, L.L.C. | 10 | $150 |
| ASD Specialty Healthcare, LLC | 2 | $106 |
| Genentech USA, Inc. | 5 | $99 |
| Array Biopharma Inc | 5 | $95 |
| Heron Therapeutics, Inc. | 3 | $72 |
| GSK | 4 | $69 |
| Tesaro, Inc. | 4 | $69 |
| Mylan Institutional Inc. | 2 | $46 |
| Lilly USA, LLC | 2 | $39 |
| Dova Pharmaceuticals | 2 | $35 |
| Sanofi | 2 | $35 |
| Secura Bio, Inc. | 1 | $23 |
| Amneal Pharmaceuticals LLC | 1 | $21 |
| Tolmar Pharmaceuticals, Inc. | 1 | $21 |
| Seqirus USA Inc | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
| Circassia Inc. | 1 | $13 |
How this compares
$6,487 in reported general payments places this provider in the 55th percentile of 682 hematology & oncology providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 74 | $30,597 |
| Sucralfate | 30 | $2,792 |
| Atorvastatin Calcium | 98 | $977 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 56 | $857 |
| Potassium Chloride | 37 | $672 |
| Latanoprost | 22 | $540 |
| ClopidogrelClopidogrel Bisulfate | 54 | $529 |
| Pantoprazole Sodium | 40 | $501 |
| Furosemide | 98 | $483 |
| Sertraline Hcl | 42 | $463 |
| Bumetanide | 17 | $394 |
| Tamsulosin Hcl | 14 | $385 |
| Losartan Potassium | 45 | $384 |
| Metolazone | 20 | $380 |
| Carvedilol | 31 | $379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $636 | $30,59774 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $21 | $28224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Greensburg
- Diwakar DavarPittsburgh$21.6M
- Jason LukePittsburgh$15M
- Stephen BagleyPhiladelphia$13.1M
- Leonard ApplemanPittsburgh$12.8M
- Jing Zhou HouPittsburgh$11.9M
- Taofeek OwonikokoPittsburgh$9.7M
- Stephen SchusterPhiladelphia$9.5M
- Pooja GhataliaPhiladelphia$8.3M
- Corey LangerPhiladelphia$7.7M
- Alfred GarfallPhiladelphia$7.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.